Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects

Pharmacotherapy

Volumn 28, Issue 12, 2008, Pages 1483-1493

  Farid, Nagy A ^a   Small, David S ^a   Payne, Christopher D ^a   Jakubowski, Joseph A ^a   Brandt, John T ^a   Li, Ying G ^a   Ernest II, C Steven ^a   Salazar, Daniel E ^b   Konkoy, Christopher ^a   Winters, Kenneth J ^a  

^a ELI LILLY AND COMPANY   (United States)

^b DAIICHI SANKYO INC   (United States)

Author keywords

Atorvastatin; Clopidogrel; Pharmacodynamics; Pharmacokinetics; Platelet aggregation; Prasugrel; Thienopyridine

Indexed keywords

ATORVASTATIN; CLOPIDOGREL; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; PRASUGREL; R 106583; R 119251; R 138727; R 95913; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; HUMAN; HUMAN EXPERIMENT; LIVER FAILURE; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NORMAL HUMAN; OPEN STUDY; PHARMACODYNAMICS; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT DURATION; VOLUNTEER;

EID: 57149084688     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.12.1483     Document Type: Article

References (44)

1. Storey RH. Biology and pharmacology of the platelet P2Y12 receptor. Curr Pharm Des 2006;12:1255-9.
2. Ding Z, Kim S, Dorsam RT, Jin J, Kunapuli SP. Inactivation of human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys 17 and Cys 270. Blood 2003;101:3908-14.
3. Sugidachi A, Asai F, Ogawa T, Inoue T, Koike H. The in vivo pharmacological profile of CS747, a novel antiplatelet agent with ADP receptor antagonist properties. Br J Pharmacol 2000;129:1439-46.
4. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction, 2002: summary article - a report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation 2002;106:1893-900.
5. Jakubowski JA, Winters KJ, Naganuma H, Wallentin L. Prasugrel, a novel thienopyridine antiplatelet agent: a review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev 2007;25:357-74.
6. Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J 2006;27:1166-73.
7. Jakubowski JA, Matsushima N, Asai F, et al. A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol 2007;63:421-30.
8. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite [online exclusive article]. Am Heart J 2007;153:e9-16. Available from http://www.ahjonline.com/article/S0002-8703(06) 00902-1/abstract.
9. Payne CD, Li YG, Small DS, et al. Increased active metabolite formation explains greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 2007;50:555-62.
10. Weerakkody GJ, Jakubowski JA, Brandt JT, et al. Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status. Am J Cardiol 2007;100:331-6.
11. Williams ET, Jones KO, Ponsler GD, et al. The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. Drug Metab Dispos 2008;36:1227-32.
12. Fayer-Rehmel JL, Eckstein JA, Farid NA, et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 2006;34:600-7.
13. Farid NA, Smith RL, Gillespie TA, et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos 2007;35:1096-104.
14. Kurihara A, Hagihara K, Kazui M, Ishizuka T, Farid NA, Ikeda T. In vitro metabolism of antiplatelet agent clopidogrel: cytochrome P450 isoforms responsible for two oxidation steps involved in the active metabolite formation [abstract]. Drug Metab Rev 2005;37(S2):99.
15. Anonymous. Physicians' desk reference. Plavix (clopidogrel) package insert. Montvale, NJ: Thomson Healthcare, 2007:918-21.
16. Tang M, Mukundan M, Yang J, et al. Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J. Pharmacol Exp Ther 2006;319:1467-76.
17. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and inhibited by atorvastatin. Drug Metab Dispos 2003;31:53-9.
18. Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007;81:735-41.
19. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003;107:32-7.
20. Neubauer H, Günesdogan B, Hanefeld C, et al. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function: a flow cytometry study. Eur Heart J 2003;24:1744-9.
21. Müller I, Besta F, Schulz C, et al. Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation 2003;108:2195-7.
22. Mitsios JV, Papathanasiou AI, Rodis FI, et al. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndrome. Circulation 2004;109:1335-8.
23. Smith SM, Judge HM, Peters G, et al. Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention. Platelets 2004;15:465-74.
24. Mukherjee D, Kline-Rogers E, Fang J, et al. Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome. Heart 2005;91:23-6.
25. Saw J, Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003;108:921-4.
26. Gorchakova O, von Beckerath N, Gawaz M, et al. Antiplatelet effects of a 600-mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary stenting. Eur Heart J 2004;25:1898-902.
27. Serebruany VL, Midei MG, Malinin AI, et al. Absence of interaction between atorvastatin or other statins and clopidogrel. Arch Intern Med 2004;164:2051-7.
28. Lim MJ, Spencer FA, Gore JM, et al. Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry. Eur Heart J 2005;26:1063-9.
29. Saw J, Brennan DM, Steinhubl SR, et al. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol 2007;50:291-5.
30. Wenaweser P, Windecker S, Billinger M, et al. Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis. Am J Cardiol 2007;99:353-6.
31. Farid NA, McIntosh M, Garofolo F, et al. Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Spectrom 2007;21:169-73.
32. Takahashi M, Pang H, Kikuchi A, et al. Stabilization of the clopidogrel active metabolite in whole blood and its assay in human plasma by LCMS/MS [abstract]. J Am Soc Mass Spectrom 2006:pS52(suppl 1):abstract MP11.
33. Jakubowski JA, Stampfer MJ, Vaillancourt R, et al. Cumulative antiplatelet effect of low-dose enteric coated aspirin. Br J Haematol 1985;60:635-42.
34. Aleil B, Meyer N, Cazenave JP, et al. High stability of blood samples for flow cytometric analysis of VASP phosphorylation to measure the clopidogrel responsiveness in patients with coronary artery disease. Thromb Haemost 2005;94:886-7.
35. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: in vivo drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labeling. Available from http://www.fda.gov/cder/guidance/2635fnl.htm. Accessed May 11, 2007.
36. Bjornsson TD, Callaghan JT, Einholf HJ, et al. The conduct of in vitro and in vivo drug-drug-interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003;31:815-32.
37. Farid NA, Jakubowski JA, Payne CD, et al. Effect of induction by rifampicin on the pharmacokinetics of prasugrel metabolites in healthy subjects [abstract]. Drug Metab Rev 2007;39(S1):125.
38. Sugidachi A, Ogawa T, Kurihara A, et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J Thromb Haemost 2007;5:1545-51.
39. Small DS, Farid NA, Payne CD, et al. Prasugrel 60 mg and clopidogrel 300 mg loading doses: a pharmacokinetic basis for the observed difference in platelet aggregation response [abstract]. Am J Cardiol 2006;98(S1):S200.
40. Geisler T, Zürn C, Paterok M, et al. Statins do not adversely affect post-interventional residual platelet aggregation and outcomes in patients undergoing coronary stenting treated by dual antiplatelet therapy. Eur Heart J 2008;29:1635-43.
41. Wienbergen H, Gitt AK, Schiele R, et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndrome taking atorvastatin versus other statin therapies. Am J Cardiol 2003;92:285-8.
42. Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, La Du BN. Current progress on esterases: from molecular structure to function. Drug Metab Dispos 2002;30:488-93.
43. Paine MF, Hart HL, Ludington SS, et al. The human intestinal cytochrome P450 "pie." Drug Metab Dispos 2006;34:880-6.
44. Wagner M, Halilbasic E, Marschall H-U, et al. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology 2005;42:420-30.